Enabling the Exchange of Clinical and Economic Data Pre-FDA Approval - Proceedings from the AMCP Partnership Forum
Webinar Recorded on December 15, 2016
Payers and other entities seek clinical and economic information related to medications and health care technologies in the pipeline 12-18 months prior to medication or technology approval. Early dissemination of information to payers would allow them to build this information into forecasting and premiums, as waiting until approval is often too late. In September, AMCP gathered a diverse group of health care stakeholders to develop recommendations for biopharmaceutical companies and health care decision makers to more easily communicate information on products awaiting Food and Drug Administration (FDA) approval. Join AMCP to learn about the recommendations that resulted from the Partnership Forum and AMCP’s efforts to improve the exchange of clinical and economic information prior to FDA approval.
- Mary Jo Carden, RPh, JD
Vice President, Government & Pharmacy Affairs
Academy of Managed Care Pharmacy
- Amy Duhig, PhD
Senior Director, Outcomes Research